Name | Number of supported studies | Average coverage | |
---|---|---|---|
peripheral blood | 13 studies | 28% ± 10% | |
lung | 11 studies | 27% ± 10% | |
kidney | 7 studies | 19% ± 2% | |
intestine | 7 studies | 22% ± 9% | |
bone marrow | 5 studies | 22% ± 7% | |
eye | 4 studies | 23% ± 6% | |
uterus | 4 studies | 31% ± 16% | |
brain | 4 studies | 26% ± 5% | |
liver | 4 studies | 29% ± 19% | |
pancreas | 3 studies | 59% ± 15% | |
placenta | 3 studies | 27% ± 7% | |
lymph node | 3 studies | 22% ± 2% |
Tissue | GTEx Coverage | GTEx Average TPM | GTEx Number of samples | TCGA Coverage | TCGA Average TPM | TCGA Number of samples |
---|---|---|---|---|---|---|
liver | 100% | 6194.29 | 226 / 226 | 100% | 410.31 | 406 / 406 |
ovary | 100% | 7083.93 | 180 / 180 | 100% | 381.11 | 430 / 430 |
skin | 100% | 8616.60 | 1809 / 1809 | 100% | 670.77 | 472 / 472 |
uterus | 100% | 8302.28 | 170 / 170 | 100% | 483.17 | 459 / 459 |
brain | 100% | 6187.65 | 2639 / 2642 | 100% | 308.37 | 705 / 705 |
thymus | 100% | 6954.06 | 652 / 653 | 100% | 338.91 | 604 / 605 |
kidney | 100% | 7500.82 | 89 / 89 | 100% | 257.16 | 898 / 901 |
lung | 100% | 7150.18 | 578 / 578 | 100% | 383.60 | 1150 / 1155 |
adrenal gland | 100% | 9991.71 | 258 / 258 | 100% | 304.44 | 229 / 230 |
esophagus | 100% | 7413.63 | 1445 / 1445 | 99% | 225.10 | 182 / 183 |
pancreas | 100% | 4020.18 | 328 / 328 | 99% | 303.84 | 177 / 178 |
intestine | 100% | 7797.28 | 966 / 966 | 99% | 328.67 | 524 / 527 |
prostate | 100% | 7760.19 | 245 / 245 | 99% | 349.94 | 499 / 502 |
breast | 100% | 8223.22 | 459 / 459 | 99% | 431.13 | 1111 / 1118 |
stomach | 100% | 6016.57 | 359 / 359 | 99% | 281.62 | 284 / 286 |
bladder | 100% | 7662.62 | 21 / 21 | 99% | 434.35 | 499 / 504 |
adipose | 100% | 8244.17 | 1204 / 1204 | 0% | 0 | 0 / 0 |
blood vessel | 100% | 8639.00 | 1335 / 1335 | 0% | 0 | 0 / 0 |
eye | 0% | 0 | 0 / 0 | 100% | 449.68 | 80 / 80 |
lymph node | 0% | 0 | 0 / 0 | 100% | 650.66 | 29 / 29 |
muscle | 100% | 7461.42 | 803 / 803 | 0% | 0 | 0 / 0 |
spleen | 100% | 8078.38 | 241 / 241 | 0% | 0 | 0 / 0 |
tonsil | 0% | 0 | 0 / 0 | 100% | 404.10 | 45 / 45 |
ureter | 0% | 0 | 0 / 0 | 100% | 321.54 | 1 / 1 |
heart | 99% | 5787.53 | 852 / 861 | 0% | 0 | 0 / 0 |
peripheral blood | 98% | 7050.23 | 915 / 929 | 0% | 0 | 0 / 0 |
abdomen | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
bone marrow | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
diaphragm | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
gingiva | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasal cavity | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasopharynx | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nose | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
placenta | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
spinal column | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
GO_0002862 | Biological process | negative regulation of inflammatory response to antigenic stimulus |
GO_0043161 | Biological process | proteasome-mediated ubiquitin-dependent protein catabolic process |
GO_0000502 | Cellular component | proteasome complex |
GO_0070062 | Cellular component | extracellular exosome |
GO_0036064 | Cellular component | ciliary basal body |
GO_0005839 | Cellular component | proteasome core complex |
GO_0005654 | Cellular component | nucleoplasm |
GO_0005829 | Cellular component | cytosol |
GO_0019774 | Cellular component | proteasome core complex, beta-subunit complex |
GO_0005737 | Cellular component | cytoplasm |
GO_0005739 | Cellular component | mitochondrion |
GO_0005634 | Cellular component | nucleus |
GO_0001530 | Molecular function | lipopolysaccharide binding |
GO_0005515 | Molecular function | protein binding |
Gene name | PSMB4 |
Protein name | Proteasome subunit beta type-4 (26 kDa prosomal protein) (HsBPROS26) (PROS-26) (Macropain beta chain) (Multicatalytic endopeptidase complex beta chain) (Proteasome beta chain) (Proteasome chain 3) (HsN3) |
Synonyms | PROS26 |
Description | FUNCTION: Non-catalytic component of the 20S core proteasome complex involved in the proteolytic degradation of most intracellular proteins. This complex plays numerous essential roles within the cell by associating with different regulatory particles. Associated with two 19S regulatory particles, forms the 26S proteasome and thus participates in the ATP-dependent degradation of ubiquitinated proteins. The 26S proteasome plays a key role in the maintenance of protein homeostasis by removing misfolded or damaged proteins that could impair cellular functions, and by removing proteins whose functions are no longer required. Associated with the PA200 or PA28, the 20S proteasome mediates ubiquitin-independent protein degradation. This type of proteolysis is required in several pathways including spermatogenesis (20S-PA200 complex) or generation of a subset of MHC class I-presented antigenic peptides (20S-PA28 complex). SMAD1/OAZ1/PSMB4 complex mediates the degradation of the CREBBP/EP300 repressor SNIP1. . |
Accessions | P28070 ENST00000290541.7 |